Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.81+0.02 (+0.35%)
Close on Nov 16, 2026Market cap $297.90MP/E –Yield –
Emergent BioSolutions cash
Cash and short-term investments held at the end of each period.
Emergent BioSolutions's cash was $175.70M at Sep 30, 2026. For fiscal 2025 it was $205.40M, up 94.5% from the year before. Over ten years it grew -4.1% a year on average. The highest annual figure on record is $642.60M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.40M | +94.5% |
| FY2024 | Dec 31, 2024 | $105.60M | -5.5% |
| FY2023 | Dec 31, 2023 | $111.70M | -82.6% |
| FY2022 | Dec 31, 2022 | $642.60M | +11.5% |
| FY2021 | Dec 31, 2021 | $576.30M | -7.3% |
| FY2020 | Dec 31, 2020 | $621.50M | +269.9% |
| FY2019 | Dec 31, 2019 | $168.00M | +49.5% |
| FY2018 | Dec 31, 2018 | $112.40M | -37.3% |
| FY2017 | Dec 31, 2017 | $179.30M | -34.2% |
| FY2016 | Dec 31, 2016 | $272.50M | -12.9% |
| FY2015 | Dec 31, 2015 | $312.80M | +11.5% |
| FY2014 | Dec 31, 2014 | $280.50M | +56.4% |
| FY2013 | Dec 31, 2013 | $179.34M | +26.6% |
| FY2012 | Dec 31, 2012 | $141.67M | -2.9% |
| FY2011 | Dec 31, 2011 | $145.87M | -14.7% |
| FY2010 | Dec 31, 2010 | $171.05M | +66.2% |
| FY2009 | Dec 31, 2009 | $102.92M | +12.5% |
| FY2008 | Dec 31, 2008 | $91.47M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $175.70M | -28.4% |
| Q2 FY2026 | Jun 30, 2026 | $139.70M | -47.7% |
| Q1 FY2026 | Mar 31, 2026 | $160.30M | +7.5% |
| Q4 FY2025 | Dec 31, 2025 | $205.40M | +94.5% |
| Q3 FY2025 | Sep 30, 2025 | $245.50M | +63.8% |
| Q2 FY2025 | Jun 30, 2025 | $267.30M | +283.5% |
| Q1 FY2025 | Mar 31, 2025 | $149.10M | +89.9% |
| Q4 FY2024 | Dec 31, 2024 | $105.60M | -5.5% |
| Q3 FY2024 | Sep 30, 2024 | $149.90M | +70.7% |
| Q2 FY2024 | Jun 30, 2024 | $69.70M | -21.3% |
| Q1 FY2024 | Mar 31, 2024 | $78.50M | -81.8% |
| Q4 FY2023 | Dec 31, 2023 | $111.70M | -82.6% |
| Q3 FY2023 | Sep 30, 2023 | $87.80M | -63.6% |
| Q2 FY2023 | Jun 30, 2023 | $88.60M | -75.3% |
| Q1 FY2023 | Mar 31, 2023 | $430.20M | -1.3% |
| Q4 FY2022 | Dec 31, 2022 | $642.60M | +11.5% |
| Q3 FY2022 | Sep 30, 2022 | $240.90M | -40.4% |
| Q2 FY2022 | Jun 30, 2022 | $358.30M | -20.0% |
| Q1 FY2022 | Mar 31, 2022 | $436.00M | -20.4% |
| Q4 FY2021 | Dec 31, 2021 | $576.30M | -7.3% |
| Q3 FY2021 | Sep 30, 2021 | $404.00M | -2.7% |
| Q2 FY2021 | Jun 30, 2021 | $447.70M | +66.4% |
| Q1 FY2021 | Mar 31, 2021 | $548.00M | +201.6% |
| Q4 FY2020 | Dec 31, 2020 | $621.50M | +269.9% |
| Q3 FY2020 | Sep 30, 2020 | $415.20M | +197.8% |
| Q2 FY2020 | Jun 30, 2020 | $269.00M | +51.5% |
| Q1 FY2020 | Mar 31, 2020 | $181.70M | +32.2% |
| Q4 FY2019 | Dec 31, 2019 | $168.00M | +49.5% |
| Q3 FY2019 | Sep 30, 2019 | $139.40M | -59.0% |
| Q2 FY2019 | Jun 30, 2019 | $177.60M | -7.2% |
| Q1 FY2019 | Mar 31, 2019 | $137.40M | -16.5% |
| Q4 FY2018 | Dec 31, 2018 | $112.40M | -37.3% |
| Q3 FY2018 | Sep 30, 2018 | $340.40M | -0.2% |
| Q2 FY2018 | Jun 30, 2018 | $191.30M | -39.4% |
| Q1 FY2018 | Mar 31, 2018 | $164.60M | -39.1% |
| Q4 FY2017 | Dec 31, 2017 | $179.30M | -34.2% |
| Q3 FY2017 | Sep 30, 2017 | $340.99M | – |
| Q2 FY2017 | Jun 30, 2017 | $315.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $270.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $272.50M | – |
See a number that looks wrong?